ProtagenicTherapeuticsInc_OTC_PTIX_202310-K.pdf

1、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549 FORM 10-K ANNUAL REPORT UNDER SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For fiscal year ended:December 31,2023 OR TRANSITION REPORT UNDER SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition

2、period from _ to _ Commission file number:001-12555 Protagenic Therapeutics,Inc.(Exact name of registrant as specified in its charter)Delaware 06-1390025(State or other jurisdiction of(I.R.S.Employerincorporation or organization)Identification No.)149 Fifth Avenue New York,New York 10010(Address of

3、principal executive offices)(Zip Code)Registrants telephone number,including area code:(212)994-8200 Securities registered under Section 12(b)of the Exchange Act:Title of each class Name of exchange on which registeredCommon Stock,par value$0.0001,PTIX Nasdaq Capital MarketCommon Stock Purchase Warr

4、ant,PTIXW Nasdaq Capital Market Securities registered under Section 12(g)of the Exchange Act:Common Stock,$0.0001 par value(Title of class)Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the regist

5、rant is not required to file reports pursuant to Section 13 or 15(d)of the Exchange Act.Yes No Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Exchange Act during the preceding 12 months(or for such shorter period thatthe regist

6、rant was required to file such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted posted pursuant to Rule 405 of Regulation S-T(232.405